Alaunos Therapeutics
TCRT
137 hedge funds and large institutions have $115M invested in Alaunos Therapeutics in 2018 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 34 increasing their positions, 40 reducing their positions, and 20 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
30% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 20
5% more funds holding
Funds holding: 131 → 137 (+6)
0.02% more ownership
Funds ownership: 0.27% → 0.29% (+0.02%)
6% less call options, than puts
Call options by funds: $2.63M | Put options by funds: $2.8M
15% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 40
38% less capital invested
Capital invested by funds: $185M → $115M (-$70.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
MSD Partners
New York
|
+$20M |
| 2 |
MVP
Miller Value Partners
Sarasota,
Florida
|
+$11.7M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.66M |
| 4 |
II
Ibex Investors
Denver,
Colorado
|
+$1.06M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$918K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TS
Third Security
Radford,
Virginia
|
-$14.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.44M |
| 3 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
-$1.76M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.65M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.46M |
TCRT Hedge Fund Activity: Q4 2018 in Review
137 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q4 2018, worth a combined $115M — down 38% from $185M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new TCRT positions and 20 closed out — a net gain of 6 holders — while 34 added to existing stakes and 40 trimmed.
The largest buyer was MSD Partners, adding an estimated $20M. The largest seller was Third Security, cutting an estimated $14.1M.
- 137 institutional investors held Alaunos Therapeutics (TCRT) as of Q4 2018, up from 131 in Q3 2018.
- Funds reported $115M of Alaunos Therapeutics stock for Q4 2018, down 38% quarter-over-quarter.
- 26 funds opened new Alaunos Therapeutics positions in Q4 2018 and 20 closed out, a net change of +6 holders.
- The largest Alaunos Therapeutics buyer in Q4 2018 was MSD Partners, an estimated $20M added.
- The largest Alaunos Therapeutics seller in Q4 2018 was Third Security, an estimated $14.1M sold.
Based on aggregated 13F filings for Q4 2018.